Multicenter comparison of PEG-IFN alpha 2a or alpha 2b plus ribavirin for treatment-naive HCV patient in Korean populationopen access
- Jin, Young-Joo; Lee, Jin-Woo; Lee, Jung Il; Park, Sang Hoon; Park, Choong Kee; Kim, Young Seok; Jeong, Sook-Hyang; Kim, Yun Soo; Kim, Ju Hyun; Hwang, Seong Gyu; Rim, Kyu Sung; Yim, Hyung Joon; Cheong, Jae Youn; Cho, Sung Won; Lee, June Sung; Park, Young Min; Jang, Jeong Won; Lee, Chun Kyon; Sohn, Joo Hyun; Yang, Jin Mo; Han, Seungbong
- Issue Date
- BIOMED CENTRAL LTD
- Chronic hepatitis C; Pegylated interferon alfa-2a; Pegylated interferon alfa-2b; Ribavirin; Sustained virological response
- BMC GASTROENTEROLOGY, v.13
- Journal Title
- BMC GASTROENTEROLOGY
- Background: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naive chronic HCV patients. Patients received PEG-IFN alfa-2a (180 mu g/week; n=402) or PEG-IFN alfa-2b (1.5 mu g/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (<= 50 and >50), HCV viral load (IU/mL) (<= 7x10(5) and >7x10(5)), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.